Last edition
News about "AstraZeneca"
IMFINZI from AstraZeneca has received US approval in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer, supported by Phase III POTOMAC trial data showing a 32 percent reduction in the risk of disease recurrence, progression, or death after one year of IMFINZI added to BCG vs. BCG alone.
AstraZeneca | 29/05/2026 | By News Bureau
Camizestrant Plus CDK4/6 Inhibitor Recommended for EU Approval in Advanced ER-Positive Breast Cancer
Camizestrant plus a CDK4/6 inhibitor receives CHMP recommendation for EU approval in first-line advanced ER-positive breast cancer, supported by phase 3 SERENA-6 trial results showing a 56 percent reduction in disease progression or death.
AstraZeneca | 25/05/2026 | By News Bureau
AstraZeneca Wins US Approval for Baxfendy, First Aldosterone Synthase Inhibitor for Hypertension
AstraZeneca receives US approval for Baxfendy, the first Aldosterone Synthase Inhibitor (ASI) for adults with hypertension, supported by phase 3 BaxHTN trial results showing significant reductions in systolic blood pressure.
AstraZeneca | 20/05/2026 | By News Bureau
US FDA Approves Enhertu for New Early Breast Cancer Indications
Enhertu receives new US approvals for use before and after surgery in HER2-positive breast cancer, supported by positive DESTINY-Breast11 and DESTINY-Breast05 phase 3 trial results.
AstraZeneca | 18/05/2026 | By News Bureau
AstraZeneca Wins US FDA Approval for Fasenra in Hypereosinophilic Syndrome
AstraZeneca receives US Food and Drug Administration (FDA) approval for Fasenra to treat hypereosinophilic syndrome, supported by positive phase 3 NATRON trial results.
AstraZeneca | 16/05/2026 | By News Bureau
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
AstraZeneca | 15/05/2026 | By News Bureau
US FDA Recommends AstraZeneca's TRUQAP for PTEN-Deficient Prostate Cancer
US Food and Drug Administration (FDA) advisory panel backs TRUQAP (capivasertib) with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer, based on positive phase 3 CAPItello-281 results showing favorable benefit-risk.
AstraZeneca | 01/05/2026 | By News Bureau
AstraZeneca Wins US Approval for Self-Administered Saphnelo Pen for Lupus Treatment
AstraZeneca launches a self-injectable version of Saphnelo, offering lupus patients a more convenient treatment option with proven efficacy and safety.
AstraZeneca | 28/04/2026 | By News Bureau | 123
AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial
AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.
AstraZeneca | 21/04/2026 | By News Bureau | 103
Syneron Bio Raises USD 150 Million in Series B Funding
Syneron Bio raises USD 150 million in Series B to advance its Synova macrocyclic peptide platform and accelerate pipeline development towards clinical stages.
AstraZeneca | 06/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy